SCOPUS 정보 검색 플랫폼

Journal of Cutaneous Medicine and Surgery

Volumn 15, Issue 3, 2011, Pages 183-184

Exacerbation and change of psoriasis morphology in a patient treated with ustekinumab

(4) Kerdel, Francisco A a Valeron Almazán, Pedro b Vitiello, Magalys a Abuchar, Adriana a

a UNIVERSITY OF MIAMI HOSPITAL (United States)

b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ADULT; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFECT; ERYTHRODERMA; FEMALE; HUMAN; LETTER; MEDICAL HISTORY; PATIENT CARE PLANNING; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUSTULE; REBOUND;

ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; PSORIASIS;

EID: 79956034032 PISSN: 12034754 EISSN: None Source Type: Journal
DOI: 10.2310/7750.2011.10114 Document Type: Letter

Times cited : (3)

References (5)

1
- 43449111187
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-Week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- DOI 10.1016/S0140-6736(08)60725-4, PII S0140673608607254
- Leonardi CI, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74, doi:10.1016/S0140-6736(08)60725-4. (Pubitemid 351671883)
- (2008) The Lancet , vol.371 , Issue.9625 , pp. 1665-1674
- Leonardi, C.L.¹ Kimball, A.B.² Papp, K.A.³ Yeilding, N.⁴ Guzzo, C.⁵ Wang, Y.⁶ Li, S.⁷ Dooley, L.T.⁸ Gordon, K.B.⁹

2
- 43449139402
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- DOI 10.1016/S0140-6736(08)60726-6, PII S0140673608607266
- Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84, doi:10.1016/S0140-6736(08)60726-6. (Pubitemid 351671884)
- (2008) The Lancet , vol.371 , Issue.9625 , pp. 1675-1684
- Papp, K.A.¹ Langley, R.G.² Lebwohl, M.³ Krueger, G.G.⁴ Szapary, P.⁵ Yeilding, N.⁶ Guzzo, C.⁷ Hsu, M.-C.⁸ Wang, Y.⁹ Li, S.¹⁰ Dooley, L.T.¹¹ Reich, K.¹²

3
- 12444266783
- Definitions of measures of effect duration for psoriasis treatments
- DOI 10.1001/archderm.141.1.82
- Gordon KB, Feldman FR, Koo JY, et al. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol 2005;141:82-4, doi:10.1001/archderm.141.1.82. (Pubitemid 40144447)
- (2005) Archives of Dermatology , vol.141 , Issue.1 , pp. 82-84
- Gordon, K.B.¹ Feldman, S.R.² Koo, J.Y.M.³ Menter, A.⁴ Rolstad, T.⁵ Krueger, G.⁶

4
- 58849118867
- Population pharmacokinetic modelling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis
- doi:10.1177/0091270008329556
- Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modelling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 2009;49:162-75, doi:10.1177/0091270008329556.
- (2009) J Clin Pharmacol , vol.49 , pp. 162-175
- Zhu, Y.¹ Hu, C.² Lu, M.³

5
- 74249094930
- Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
- Griffiths CEM, Strober B, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Medicine 2010;362:118-28.
- (2010) N Engl J Medicine , vol.362 , pp. 118-128
- Griffiths, C.E.M.¹ Strober, B.² Van De Kerkhof, P.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.